We are live on ! Find out more
HQL

abrdn Life Sciences Investors

63 hedge funds and large institutions have $58.4M invested in abrdn Life Sciences Investors in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 14

12% more capital invested

Capital invested by funds: $52.3M → $58.4M (+$6.12M)

2.4% more ownership

Funds ownership: 14.61%17.01% (+2.4%)

3% less funds holding

Funds holding: 6563 (-2)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
63
Holders Change
-2
Holders Change %
-3.08%
% of All Funds
1.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
30
Reduced
14
Closed
7
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q3 2022 in Review

63 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q3 2022, worth a combined $58.4M — up 12% from $52.3M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of HQL and 6 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 30 added.

The largest buyer was Cornerstone Advisors, adding an estimated $2.47M. The largest seller was Advisors Asset Management, cutting an estimated $749K.

  • 63 institutional investors held abrdn Life Sciences Investors (HQL) as of Q3 2022, down from 65 in Q2 2022.
  • Funds reported $58.4M of abrdn Life Sciences Investors stock for Q3 2022, up 12% quarter-over-quarter.
  • 6 funds opened new abrdn Life Sciences Investors positions in Q3 2022 and 7 closed out, a net change of -1 holder.
  • The largest abrdn Life Sciences Investors buyer in Q3 2022 was Cornerstone Advisors, an estimated $2.47M added.
  • The largest abrdn Life Sciences Investors seller in Q3 2022 was Advisors Asset Management, an estimated $749K sold.

Based on aggregated 13F filings for Q3 2022.